MX2020005530A - Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas. - Google Patents

Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas.

Info

Publication number
MX2020005530A
MX2020005530A MX2020005530A MX2020005530A MX2020005530A MX 2020005530 A MX2020005530 A MX 2020005530A MX 2020005530 A MX2020005530 A MX 2020005530A MX 2020005530 A MX2020005530 A MX 2020005530A MX 2020005530 A MX2020005530 A MX 2020005530A
Authority
MX
Mexico
Prior art keywords
proteins
modified norovirus
norovirus
vlps
modified
Prior art date
Application number
MX2020005530A
Other languages
English (en)
Inventor
Marc Andre D'aoust
Pierre Olivier Lavoie
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of MX2020005530A publication Critical patent/MX2020005530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Se proporcionan ácidos nucleicos que codifican proteínas VP1 de norovirus modificadas, y se proporcionan VLP que comprenden una o más de las proteínas VP1 de norovirus modificadas. También se describen métodos para la proteína VP1 de norovirus modificada y la producción de VLP de norovirus en plantas, porciones de la planta o una célula de una planta.
MX2020005530A 2017-11-30 2018-11-30 Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas. MX2020005530A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593006P 2017-11-30 2017-11-30
US201862712744P 2018-07-31 2018-07-31
PCT/CA2018/051530 WO2019104439A1 (en) 2017-11-30 2018-11-30 Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins

Publications (1)

Publication Number Publication Date
MX2020005530A true MX2020005530A (es) 2021-01-15

Family

ID=66663733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005530A MX2020005530A (es) 2017-11-30 2018-11-30 Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas.

Country Status (14)

Country Link
US (2) US11602558B2 (es)
EP (1) EP3717648A4 (es)
JP (1) JP2021503962A (es)
KR (1) KR20200092363A (es)
CN (1) CN111727255A (es)
AU (1) AU2018375695A1 (es)
BR (1) BR112020010799A2 (es)
CA (1) CA3083857A1 (es)
IL (1) IL274736A (es)
MX (1) MX2020005530A (es)
RU (1) RU2020116307A (es)
SG (1) SG11202004668WA (es)
WO (1) WO2019104439A1 (es)
ZA (1) ZA202003831B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7420339B2 (ja) 2019-10-11 2024-01-23 学校法人北里研究所 変異ノロウイルス粒子とその生産方法
US20230381293A1 (en) * 2020-10-14 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Stabilized norovirus virus-like particles as vaccine immunogens
CN113481328B (zh) * 2021-07-23 2023-10-27 中国科学院微生物研究所 用于检测临床样本中gi.5型诺如病毒的试剂盒及专用引物
CN118126202A (zh) * 2024-05-07 2024-06-04 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201502490YA (en) 2006-09-29 2015-05-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
WO2010017542A1 (en) 2008-08-08 2010-02-11 Ligocyte Pharmaceuticals, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
PT3354657T (pt) * 2009-09-22 2022-05-06 Medicago Inc Método de preparação de proteínas derivadas de plantas
EP2956169B1 (en) * 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
EP2994163B1 (en) * 2013-05-09 2019-08-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
US11433146B2 (en) * 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
EP3452493A1 (en) * 2016-05-04 2019-03-13 CureVac AG Nucleic acid molecules and uses thereof
EP3601580A4 (en) * 2017-03-23 2021-01-06 Medicago Inc. NOROVIRUS FUSION PROTEINS AND VLPS WITH NOROVIRUS FUSION PROTEINS

Also Published As

Publication number Publication date
RU2020116307A (ru) 2021-12-30
IL274736A (en) 2020-07-30
JP2021503962A (ja) 2021-02-15
EP3717648A1 (en) 2020-10-07
KR20200092363A (ko) 2020-08-03
ZA202003831B (en) 2023-10-25
SG11202004668WA (en) 2020-06-29
WO2019104439A1 (en) 2019-06-06
US20200330583A1 (en) 2020-10-22
EP3717648A4 (en) 2021-12-01
AU2018375695A1 (en) 2020-06-11
CN111727255A (zh) 2020-09-29
US11602558B2 (en) 2023-03-14
US20230293663A1 (en) 2023-09-21
CA3083857A1 (en) 2019-06-06
BR112020010799A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
ZA202003831B (en) Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
EP3387893A4 (en) Kit for producing plant growth medium, method for producing plant growth medium, and method for recycling used plant growth medium
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
EP3009505A4 (en) Recombinant strain producing l-amino acids, constructing method therefor and method for producing l-amino acids.
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
KR20180084680A (ko) 식물 세포에서의 목적 단백질 발현을 위한 재조합 벡터
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX368442B (es) Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
PH12017502215A1 (en) Recombinant microorganism for improve production of fine chemicals
MY189932A (en) Recombinant microorganism for improved production of alanine
EA201892624A1 (ru) Растения, дающие бессемянные плоды
WO2017017028A8 (en) Catalytically active protein aggregates and methods for producing the same
WO2016134213A3 (en) Enhanced protein expression
PH12017500047A1 (en) Dual cistronic bacterial expression system
EP3162892A4 (en) Method for culturing adhesive cells, culture vessel, and method for producing protein
EP3395939A4 (en) TANK OF CULTURAL SORTING, CULTURE AND GROWTH; AND METHOD OF CELL SORTING, CULTURE AND GROWTH
WO2016011179A3 (en) Methods of increasing crop yield under abiotic stress
MX367829B (es) Métodos para mejoramiento de plantas.
MX2013012986A (es) Plantas que tienen uno o mas rasgos mejorados relacionados con el rendimento y un metodo para producirlas.
WO2015023051A3 (ko) 광생물 반응기를 이용한 미세조류 배양과 이를 이용한 양식사료 제조시스템 및 그 제조방법